Oral presentation – SFNV 2022
🔬🧠 “Gluno(zu)mab : a disruptive strategy to treat neurological disorders” // “Gluno(zu)mab : une stratégie unique au monde pour traiter les maladies neurovasculaires”
🎤 Dr. Manuel BLANC, CEO of Lys Therapeutics is presenting on November 18, 2022 during the #aviesan session (French National Alliance for Life Sciences and Healthcare) during the 27th Days of the French Society of Neurovascular (#SFNV) in Paris new promising data with Lys Therapeutics’s lead candidate in ischemic stroke.
With Institut BB@C – Blood and Brain @ Caen normandie, Inserm, Inserm Transfert, Université de Caen Normandie and CYCERON.
—
Link for the full program: https://lnkd.in/eR2bGSVe
—
#SFNV #aviesan #Stroke #neurosciences #patients #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #brain #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #biotherapy #Glunomab #Glunozumab
🧠 Sharing a enriching experience at the 28th Congress of the SFNV – Société Française Neuro-Vasculaire
💬 Dr. Manuel BLANC, our President and co-founder, and Dr. Jean-Baptiste BERTRAND, our Head of Clinical Operations, are engaging in stimulating discussions at the Palais des Congrès in #Lille. Fruitful meetings aimed at building collaborations and collectively addressing the crucial challenges in #stroke management.
#LysTherapeutics #SFNV #SFNV2023 #Stroke
SFNV Société Française Neuro-Vasculaire